A 2017 observational study that analyzed real-world tumor responses in patients with NSCLC or advanced melanoma who received denosumab in combination with CTLA-4 or PD-1 inhibitors showed a significant association between longer exposure to concomitant therapy and ORR. This evidence concerns the gene CTLA4 and melanoma.